Cyclin-dependent kinase (CDK) and mitogen-activated protein kinase (MAPK) phosphorylate the rat glucocorticoid receptor in vitro at distinct sites that together correspond to the major phosphorylated receptor residues observed in vivo; MAPK phosphorylates receptor residues threonine 171 and serine 246, whereas multiple CDK complexes modify serines 224 and 232. Mutations in these kinases have opposite effects on receptor transcriptional activity in vivo. Receptor-dependent transcriptional enhancement is reduced in yeast strains deficient in the catalytic (p34
The glucocorticoid receptor (GR) is a member of the intracellular receptor superfamily of transcriptional regulatory proteins. The hormone-receptor complex binds specific DNA sequences and modulates transcription from nearby promoters, whereas the unliganded aporeceptor is competent only for hormone binding (5, 41, 42) . Although GR is expressed in virtually all mammalian cell types, it regulates expression of distinct sets of responsive genes in a tissue-and cell-typespecific manner.
Like other transcriptional regulatory proteins, GR is a phosphoprotein (15, 19, 31) . The aporeceptor is phosphorylated, with additional phosphorylation events occurring in conjunction with ligand binding (18, 32) . Receptor phosphorylation occurs on serine and threonine residues in both the presence and the absence of hormone and is reportedly subject to cell cycle-related changes (20, 21) . The hormone-dependent increase in receptor phosphorylation fueled speculation that phosphorylation may modulate subcellular localization, DNA binding, or transcriptional regulation (3, 10, 18) .
The majority of the phosphorylated residues lie within an N-terminal region of the receptor involved in transcriptional enhancement and repression (4, 14, 33) . Recently, four major sites of phosphorylation on the rat GR have been identified in hepatoma cells and in yeast (Saccharomyces cerevisiae) (25) . It was shown that phosphorylation of S224 and S232 increases in the presence of hormone agonists, whereas residues T171 and S246 are phosphorylated constitutively. In each case, the phosphorylated residues are followed by proline, thus corresponding to favored contexts for cyclin-dependent kinases (CDKs) and mitogen-activated protein kinases (MAPKs). To determine what enzymes are involved in phosphorylating GR, we first surveyed a battery of serine/threonine kinases for their capacities to phosphorylate the receptor in vitro at the sites identified in vivo. We then measured the transcriptional activity of the receptor in yeast strains bearing genetic defects in candidate kinases to assess their effects on GR function in vivo.
MATERIALS AND METHODS

Purification of receptor derivatives.
A wild-type rat GR derivative containing N-terminal amino acids 106 to 318 or receptor mutants with single amino acid substitutions (T171A, S224A, S224T, S232A, and S232T) were expressed in Escherichia coli as glutathione S-transferase (GST) fusion proteins (GST-GR). Cells transformed with the GST-GR constructs were grown in 50 ml of LuriaBertani medium (LB) plus ampicillin (100 g/ml) overnight at 37°C, subcultured at a 1:10 dilution into 500 ml of LB plus ampicillin, and grown for 1 h at 37°C, and protein expression was induced with 0.2 mM isopropyl-thio-␤-D-galactoside (Fisher Scientific, Fair Lawn, N.J.) for 3 h. The cells were pelleted, resuspended in 6 ml of phosphate-buffered saline supplemented with protease inhibitors, 1 mM phenylmethylsulfonyl fluoride (Sigma, St. Louis, Mo.), and 1 g each of aprotinin, pepstatin A, and leupeptin (Boehringer Mannheim Biochemicals, Indianapolis, Ind.) per ml, and lysed by sonication. Triton X-100 (Bio-Rad, Richmond, Calif.) was then added to a final concentration of 1%, and the lysates were centrifuged at 4°C for 20 min at 12,000 ϫ g. The fusion protein was purified from clarified bacterial lysates on glutathione-Sepharose beads (Pharmacia Biotech, Uppsala, Sweden) and eluted five times with 1 ml of 5 mM reduced glutathione (Sigma) in 50 mM Tris-HCl (pH 8.0). A 10-l aliquot of each fraction was boiled in an equal volume of 2ϫ sodium dodecyl sulfate (SDS) sample buffer and run on SDS-10% polyacrylamide gel electrophoresis (PAGE) gels to visualize the expressed receptor protein (Ͻ95% pure) by Coomassie blue staining. The most concentrated fractions (1 mg/ml) were pooled and used as substrates for the in vitro kinase assays.
Generation of cyclin-CDK complexes expressed in baculovirus. High Five insect cells were maintained in Ex-Cell insect culture medium (Invitrogen, San Diego, Calif.) at 27°C. Baculovirus vectors (10 Ϫ7 PFU) engineered to express human cyclins A, B, and E as well as CDK2 and CDC2 were used separately or in combination to infect cells to generate proteins for in vitro kinase assays (see below). To generate the cyclin A-CDK2 complex, cells (ϳ10 7 cells/100-mm dish) were coinfected with 0.5 ml of each virus in a final volume of 2.5 ml for 2 h at 27°C and refed with 10 ml of Ex-Cell medium. Two days after infection, the cells were lysed on ice for 1 h in 0.5 ml of 120 mM NaCl-50 mM Tris-HCl (pH 8.0)-0.5% Nonidet P-40-1 mM EDTA-1 mM dithiothreitol (DTT) with protease inhibitors (1-g/ml aprotinin, 1-g/ml leupeptin, 1-g/ml pepstatin A, 1 mM phenylmethylsulfonyl fluoride)-phosphatase inhibitors (1.0 mM NaF, 10 mM ␤-glycerophosphate, 1.0 mM sodium orthovanadate). The lysates were cleared by centrifugation at 12,000 ϫ g for 10 min at 4°C, transferred to a microcentrifuge tube, and stored at Ϫ80°C.
In vitro kinase assays. Various cyclins and CDKs (cyclins A, B, and E paired with CDK2 and cyclins A and B paired with CDC2) were expressed in insect 5B cells as described above. Purified and activated recombinant MAPK (ERK2; 50,000 U/ml) was obtained from New England Biolabs (NEB Inc., Beverly, Mass.). Histone H1 (Boehringer Mannheim) was used as a control substrate for cyclin-CDK activity. Myelin basic protein (MBP; Boehringer Mannheim) was used as a control for MAPK function.
Kinase reactions were performed by binding 2 g of substrate GR derivatives to 100 l of a 50% slurry of glutathione beads for 20 min on ice and washing the unbound receptor twice with DK buffer (50 mM potassium phosphate [pH 7.15], 10 mM MgCl 2 , 5 mM NaF, 5 mM DTT, supplemented with protease inhibitors as described above). Approximately 5 l of whole-cell lysates containing cyclin-CDK complexes (25 g of total protein) or 50 U (50 U/l) of recombinant ERK2 was added to the immobilized receptor along with 25 M ATP, 10 mM MgCl 2 , 1 mM DTT, and [␥-32 P]ATP (100 Ci) in a total volume of 100 l. The kinase reactions were allowed to proceed for 30 min at room temperature with continuous shaking. The beads were then washed five times with 1 ml of phosphatebuffered saline to remove unincorporated radioisotope. The labeled receptor protein was released by boiling for 2 min in 50 l of 2ϫ SDS sample buffer, run on SDS-10% PAGE gels, and visualized by Coomassie blue staining. Histone H1 and MBP (2 g per reaction mixture) were phosphorylated in solution under the assay conditions used for GST-GR. The gels were dried, and phosphorylation of substrates was visualized by autoradiography.
Phosphopeptide mapping and phosphoamino acid analysis. Polyacrylamide gels containing the labeled receptor were washed three times for 10 min each in 500 ml of water and dried between cellophane sheets. Following autoradiography, the GR band was excised and the rehydrated gel slice was placed into a Microfuge tube at room temperature in 50 mM ammonium acetate (pH 4.0)-1 mM DTT-50 g of V8 protease (endoproteinase Glu-C; Boehringer Mannheim). After 10 h at 25°C, an additional 50 g of V8 protease was added, and incubation was continued for 5 h at 25°C. The samples were centrifuged for 5 min at 12,000 ϫ g, and the supernatant containing the digested peptides was evaporated to dryness. The peptides were resuspended in 500 l of water, dried, washed again, and dissolved in 10 l of electrophoresis buffer containing 15% acetic acid and 5% formic acid. The peptides were electrophoresed in the same buffer on thin-layer chromatography (TLC) plates (microcrystalline cellulose adsorbent without fluorescent indicator; Kodak) at 1,000 V for 50 min. The plates were then dried and subjected to ascending chromatography in the second dimension for 3.5 h with 37.5% butanol-25% pyridine-7.5% acetic acid, air dried, and exposed to film (6) .
For phosphoamino acid analysis, 32 P-labeled receptor was treated as described for peptide mapping, transferred to Immobilon paper (Millipore, Bedford, Mass.), and hydrolyzed in 100 l of 6 M HCl (Pierce, Rockford, Ill.) by heating to 110°C for 60 min. Samples were then dried and dissolved in 10 l of electrophoresis buffer (15% acetic acid, 5% formic acid). The hydrolysates were spotted onto a TLC plate, along with phosphoamino acid standards (1 l of a mixture of phosphoserine, phosphothreonine, and phosphotyrosine [Sigma] at 1 mg/ml each), and were resolved in the first and second dimensions by electrophoresis at 1,500 V for 20 min and at 1,300 V for 16 min, respectively. After drying, the plates were sprayed with 0.2% (wt/vol) ninhydrin in acetone to visualize the phosphoamino acid standards, and autoradiography was performed.
Yeast strains. (36) . Strains with mutations in the CDK (CDC28-4 and CDC28-1N) or in the S-phase-specific kinase (CDC7) were in a W303 background (MATa ade1 his3 leu2 trp1 ura3) (28) . Deletions of FUS3 and KSS1 were constructed in YPH 499a (ade2-100 his3⌬200 leu2-⌬1 lys2-801 trp1⌬63 ura3-52 and either Fus3::LEU2 or Kss1::HIS3). The strains were transformed via the lithium acetate and polyethylene glycol method with a GR expression vector and reporter plasmid containing a GR response element (GRE) placed upstream of the cyc1-lacZ gene.
Plasmids. The yeast GR expression plasmid PRS 314-GPDGR N795 contains a centromeric CEN-ARS origin, which maintains a copy number of one to two per cell as well as the rat GR cDNA downstream of the yeast glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter. Reporter plasmids p⌬s26X and p⌬s1Gs3 contain three tandem 26-bp oligonucleotides from the tyrosine aminotransferase GRE or the single pseudopalindromic GRE, respectively, inserted upstream of a minimal yeast cytochrome c 1 (CYC1) promoter, retaining only a TATA box and a transcription start site, which is fused to the E. coli ␤-galactosidase (LacZ)-coding sequences. The receptor expression vector also contains the TRP1 selectable marker, while the reporter plasmids have the URA3 gene.
␤-Galactosidase assaying. For liquid assays, overnight yeast cultures were diluted 1:5 in the selective minimal medium and treated with vehicle or hormone for the indicated times. To determine ␤-galactosidase activity, 1.5 ml of yeast cells was pelleted, and washed with LacZ buffer (10 mM KCl, 1 mM MgSO 4 , 50 mM ␤-mercaptoethanol, 100 mM NaPO 4 [pH 7.0]). The cells were pelleted again, resuspended in 50 l of LacZ buffer, and permeabilized with 50 l of CHCl 3 and 20 l of 0.1% SDS. ␤-Galactosidase substrate (o-nitrophenyl-␤-galactoside) was added to the mix (0.7 ml of 2-mg/ml solution), and after 1 to 10 min of incubation, the reaction was stopped with 0.5 ml of 1 M Na 2 CO 3 (13) . ␤-Galactosidase activities at 420 nm were determined and normalized to cell density.
RESULTS
In vitro phosphorylation of GR by cyclin-CDK complexes.
Prior to analyzing the consequences of phosphorylation on GR signaling, it is important to determine what kinases are involved in phosphorylating the receptor. The residues phosphorylated on the unliganded and hormone-bound rat GR expressed endogenously in rat hepatoma cells or in yeast have been identified (Fig. 1A) . GR is phosphorylated on residues T171, S224, S232, and S246, with agonist binding increasing phosphorylation at S224 and S232 (25) . Inspection of the sequence contexts of these receptor phosphorylation sites (Ser/ Thr-Pro) suggests that they may be modified by several kinases, including those from the CDK and the MAPK families (Fig.  1A) .
To determine whether GR is a substrate for CDKs, MAPKs, or other kinases, we developed a simple in vitro kinase assay. A purified receptor derivative containing N-terminal amino acids 106 to 318 with four major phosphorylation sites (T171, S224, S232, and S246) was expressed in E. coli as a GST fusion protein. Various cyclins and CDKs were expressed separately or in combination in 5B insect cells by using a baculovirus
FIG. 1. In vitro phosphorylation of the GR by cyclin-CDK complexes. (A)
Schematic representation of the major phosphorylation sites of the rat GR expressed in either rat hepatoma cells or yeast (S. cerevisiae); residues T171, S224, S232, and S246 (25) . Phosphorylated residues T171 and S246 are potential targets for MAPK (consensus sequence, nonpolar-X-Ser/Thr-Pro), while the sequence context surrounding S224 and S232 coincides with putative sites of phosphorylation by the CDKs (consensus sequence, Ser/Thr-Pro-X-Arg/Lys). (B) GR phosphorylation in vitro by cyclin-CDK complexes. A GST-GR fusion protein containing receptor residues 106 to 318 was expressed in E. coli and purified by glutathione-agarose affinity chromatography. The protein was used as a substrate for the in vitro kinase reactions with various cyclin-CDK complexes coexpressed in 5B insect cells with a baculovirus expression system (lanes 1, 2, 5, 6, and 9). Histone H1 was used as an independent measure of kinase activity for cyclin A-CDK2, A-CDC2, B-CDK2, and B-CDC2 complexes (lanes 3, 4, 7, and 8, respectively). The amount of histone H1 substrate used is in fivefold molar excess above that of the receptor. expression system. The kinase series included cyclins A, B, and E paired with CDK2 and cyclins A and B paired with CDC2. As a control for kinase activity and specificity, receptor phosphorylation was compared to that of established CDK substrate histone H1. As shown in Fig. 1B , the GR is phosphorylated by cyclin A-CDK2, cyclin A-CDC2, cyclin B-CDK2, cyclin B-CDC2 (Fig. 1B , lanes 1 to 2 and 5 to 6), and cyclin E-CDK2 (Fig. 1B, lane 9) . No phosphorylation occurred when either cyclin or CDK subunit was present in the reaction alone or if GST protein alone was used as the substrate (data not shown). Thus, five cyclin-CDK combinations phosphorylate the purified N-terminal domain of the GR in vitro. We tested several other kinases in our assay, including cyclic AMP (cAMP)-dependent protein kinase A (pKA), protein kinase C (pKC), casein kinases I and II (CK I and II), and S6 kinase. These kinases either failed to phosphorylate GR or phosphorylated it at sites not phosphorylated in vivo (data not shown). These results suggest that the receptor is a potential substrate for multiple cyclin-CDK complexes.
Two-dimensional peptide mapping was used to infer the amino acid residues phosphorylated in vitro by the different kinases, exploiting the known map positions of each in vivo phosphorylation site after the receptor was cleaved with V8 protease (Fig. 2E and F) . Interestingly, cyclin A-CDK2 produced a marked electrophoretic mobility shift of GST-GR to a lower-mobility species when phosphorylated in vitro, whereas cyclin E-CDK2 failed to produce this effect ( Fig. 2A) . The faster-migrating cyclin A-CDK2-phosphorylated receptor species (lower band) produced two phosphopeptides that comigrate with a pair of receptor phosphopeptides generated in vivo, V1 and V2 (Fig. 2D) . Peptide V1 encompasses receptor residues 220 to 231 and contains a single CDK consensus site at residue S224. Phosphopeptide V2 corresponds to the region spanning residues 220 through 242 and includes CDK phosphorylation sites at S232 and S224; this peptide carries a single phosphate at either S224 or S232. We observe the doubly phosphorylated version of this peptide (V3) with the slowermigrating form of GR phosphorylated by cyclin A-CDK2 (Fig.  2C) . Cyclin E-CDK2 produces peptides 1 and 2 (Fig. 2B) . However, we failed to observe the doubly phosphorylated peptide 3 with this kinase. Thus, the simplest explanation of these results is that cyclin E-CDK2 can phosphorylate S224, whereas cyclin A-CDK2 phosphorylates S232 together with S224.
Identification of GR residues phosphorylated in vitro by the cyclin A-CDK2 complex. To further establish the receptor residues that are modified by the cyclin A-CDK2 complex in vitro, we exploited the fact that most serine/threonine kinases are rather indiscriminate in modifying either serine or threonine residues at a given substrate site. We tested receptor derivatives with single serine-to-threonine substitutions at phosphorylation sites (S224T and S232T) for their abilities to be phosphorylated by the cyclin A-CDK2 complex. Receptor derivatives were phosphorylated in vitro and analyzed for their phosphoamino acid contents. For the wild-type receptor, only phosphoserine was observed when it was phosphorylated by cyclin A-CDK2 (Fig.  3A) , whereas S224T and S232T mutants contained increased amounts of phosphothreonine ( Fig. 3B and C) . These findings lend additional support to our interpretation of the mapping experiments and suggest that both S224 and S232 are modified by the cyclin A-CDK2 complex. Interdependency of GR sites phosphorylated by cyclin-CDK complexes. Since S224 and S232 are located relatively close to each other, we examined whether phosphorylation at S224 and/or S232 influences the ability of the neighboring site(s) to be modified. We mutated phosphorylation sites from serine or threonine to alanine (T171A, S224A, and S232A) and analyzed the phosphorylation of these receptor derivatives in vitro by cyclin-CDK complexes. The wild-type receptor and the T171A derivative are efficiently phosphorylated by cyclin A-CDK2 and cyclin E-CDK2 (Fig. 4A and B) . Likewise, phosphorylation of the S232A mutant is similar to that of the wild-type receptor. In contrast, phosphorylation is virtually abolished by the S224A mutation ( Fig. 4A and B) . Our previous mapping data indicate that cyclin A-CDK2 can phosphorylate the receptor at both S224 and S232. If these residues are phosphorylated independently, then one would expect a reduction in the amount of label incorporated in each mutant derivative. However, there is essentially no phosphorylation of the receptor protein when the S224A derivative is used as a substrate. To establish that the integrity of the S224A derivative is preserved, we tested it as a substrate for MAPK, which utilizes S246 as a target phosphorylation site (see below). Under the same assay conditions, MAPK readily phosphorylates the S224A mutant (Fig. 4C) , which suggests that the inability of the cyclin A-CDK2 complex to phosphorylate S224A does not result from global changes in protein conformation due to the mutation but rather reflects the specificity of the kinase with respect to a particular substrate site. The fact that the S224A mutation prevents phosphorylation at the S232 site suggests an interdependency of these two sites on each other, e.g., S224 has to be phosphorylated first, before phosphorylation of S232 can occur.
In vitro phosphorylation of GR by MAPK. As indicated above, MAPK could also phosphorylate the receptor in vitro (Fig. 5A) . Three distinct V8 phosphopeptides, V4, V5a, and V5b, are produced by MAPK phosphorylation of the receptor (Fig. 5B ). V5a and V5b result from incomplete digestion of a peptide containing a single phosphoserine site at position S246. Phosphorylation of T171 generates the V4 phosphopeptide corresponding to residues 159 to 174. Phosphorylation of T171 and S246 is not affected by ligand treatment in vivo. Together, MAP and CDK complexes account for all major receptor phosphopeptides generated in vivo.
GR transcriptional enhancement in strains with alterations in CDK or MAPK activity. To examine the effects of individual kinases on GR function in vivo, we examined the transcriptional activity of the receptor in yeast strains with defects in particular kinases. Since equivalent protein kinases in many signal transduction pathways have been evolutionarily maintained and receptor phosphorylation is conserved between yeast and mammalian cells, we might be able to use yeast strains bearing mutant kinases to infer kinase effects on GR function in mammalian cells.
In S. cerevisiae, CDC28 controls the G 1 /S and G 2 /M cell cycle transitions by association with two classes of cyclins (29) . At least three G 1 cyclin proteins (CLN 1 to 3 mammalian cell cycle. All single and double CLN deletion mutants are viable, but the CLN1 CLN2 CLN3 triple deletion is lethal (30, 37) . All single CLB deletion mutants are viable, whereas certain double and triple CLB deletions are lethal (36) .
We measured receptor-dependent transcriptional enhancement in yeast strains with defects in CDC28 under experimental conditions allowing cell cycle progression; thus, we uncoupled the effects of the kinase mutations from those of perturbations of the cell cycle. The GR and GRE-linked reporter gene were introduced into a wild-type strain and isogenic derivatives bearing two distinct temperature-sensitive alleles of CDC28, cdc28-4 and cdc28-1N (28) . As a control, the receptor reporter plasmids were introduced into a strain deficient in a non-CDK, cdc7-1. The cdc28 alleles carry missense mutations that lead to cell cycle arrest at the nonpermissive temperature of 37°C, whereas at 25°C the cells continue to cycle, albeit with an extended G 1 phase (27) . In the presence of 1 M deoxycorticosterone (DOC), a glucocorticoid agonist, receptor-dependent transcriptional enhancement at 25°C was decreased by four-to fivefold in the cdc28 strains relative to the wild type (Fig. 6A) . In contrast, hormone-dependent transcriptional enhancement of the receptor was virtually unaffected in the cdc7-1 strain. We determined by immunoblotting that the level and integrity of the receptor in each strain were similar (data not shown).
In parallel experiments, we monitored receptor-dependent transcriptional enhancement in mutants with defects in particular G 1 (CLN) and G 2 (CLB) cyclins. The GR and a GRElinked reporter gene were introduced into an isogenic set of strains bearing various CLN or CLB deletions that did not abrogate the cell cycle. We found that receptor-dependent transcriptional activity was sharply reduced (by fourfold) in a strain lacking both CLN1 and CLN3, whereas deletion of CLN1, CLN2, or CLN3 alone had no effect on receptor activity (Fig. 6B) .
Receptor activity was also compromised by deletion of particular CLB genes. Receptor-dependent transcriptional enhancement was reduced by as much as 10-fold in cells from which CLB1 and CLB2 had been deleted and by fourfold in   FIG. 6 . Phosphorylation-deficient strains with alterations in CDK or MAPK have opposite phenotypes upon transcriptional enhancement. (A) Receptor-dependent transcriptional activity in yeast strains altered in the mammalian CDK homolog CDC28. A wild-type (wt) strain (W303a) and an isogenic set of strains with defects in the CDKs CDC28-4 and CDC28-1N or in a non-CDK CDC7 were transformed with receptor expression vector PRS 314-GPD-GR N795 and a reporter gene containing a single consensus GRE. After overnight treatment with hormone (1 M DOC) at 25°C, ␤-galactosidase activity was measured. ␤-Galactosidase activity in each strain is normalized to cell density and is a mean value from two or more independent assays, with less than 10% variation. (B) Receptor-dependent transcriptional enhancement in yeast strains from which yeast G 1 cyclins (CLNs) have been deleted. A wild-type (wt) strain and an isogenic strain from which cln1, cln2, cln3, and cln1,3 were deleted were transformed with the receptor expression and reporter plasmids as described above. The cells were treated with 1 M DOC overnight at 30°C, and ␤-galactosidase activity was measured. (C) Receptor-dependent transcriptional enhancement in yeast strains from which yeast G 2 cyclins (CLBs) were deleted. A wild-type (wt) strain and an isogenic set of strains from which clb1, clb2, clb3, and clb4 were deleted were transformed with paired expression and reporter plasmids as described above, and receptor-dependent transcriptional activity was measured. (D) Receptor-dependent transcriptional enhancement in yeast strains from which the mammalian MAPK homologs FUS3 and KSS1 were deleted. A wild-type (wt) strain (YPH 499a) and an isogenic strain from which both FUS3 and KSS1 were deleted were transformed with the receptor on a low-copy-number expression vector and a reporter gene containing a single consensus GRE. Cells were treated with 1 M DOC overnight at 30°C, and ␤-galactosidase activity was measured. In all cases, ␤-galactosidase activity is normalized to cell density and is expressed as a percentage of the activity in the parental wild-type strain and represents a mean value from two or more independent assays with less than 10% variation.
CLB3-deficient strains, relative to the isogenic wild-type strains (Fig. 6C) . In the case of the clb2 mutant, we showed that the receptor phenotype segregated 2:2 and cosegregated with deletion of the clb2 gene, implicating CLB2 in receptor function (seven tetrads were tested, and cosegregation was observed in all seven). In a strain devoid of clb4, however, receptor-dependent transcriptional activity was only modestly affected. In all cases, the level and integrity of the receptor in each strain were similar to those of the wild type (data not shown). The fact that the receptor is expressed at similar levels in both the wild type and the mutant clb2 strain suggests that the effect of clb2 deletion on GR-dependent activation is not due to a general defect in transcription, since transcription from the GPD promoter expressing the receptor is not affected. Taken together, these results suggest that some, but not all, G 1 and G 2 cyclins participate in receptor-dependent transcriptional enhancement, at least in the contexts examined.
To assess the effect of MAPK on receptor activity, receptor and reporter plasmids were introduced into a yeast strain bearing deletions of FUS3 and KSS1, two of the four MAPK genes identified in yeast (29) . Receptor-dependent transcriptional activity was measured in the absence and presence of 1 M DOC and compared to that in a wild-type isogenic strain containing the same receptor and reporter genes. In contrast to the decreased receptor transcriptional activity observed in the CDC28 strains, receptor transcriptional enhancement was increased in the absence of FUS3 and KSS1 (Fig. 6D) . Together, our genetic results suggest strongly that CDK and MAPK modulate receptor function, potentiating and attenuating transcriptional enhancement, respectively.
DISCUSSION
Our experiments demonstrate that members of two distinct protein kinase families, CDK and MAPK, are capable of phosphorylating GR in vitro and together produce a pattern of the phosphorylated receptor amino acids identical to that observed in mammalian cells in vivo. In yeast, mutations in certain CDK catalytic or regulatory subunits decreased receptor-dependent transcriptional activation in vivo, indicating that CDC28 function is necessary for full receptor-mediated transcriptional enhancement. In contrast, deletion of FUS3 and KSS1 in yeast increased transcriptional activation by the receptor, suggesting that MAPK attenuates receptor function. Together, these findings suggest that the receptor is a common target for signaling by multiple kinases that affect its transcriptional activity oppositely.
Phosphorylation at multiple sites by different protein kinases could in principle affect a range of distinct receptor activities, such as dimerization, DNA binding, subcellular localization, or interaction with other proteins, including those in the transcriptional machinery. Each of these functions could be affected either positively or negatively, thereby adjusting the receptor response to changing physiological conditions.
For instance, insulin counteracts the physiological actions of glucocorticoids and blunts receptor-dependent transcriptional responses in certain cells (8) . The attenuation of receptor transcriptional enhancement by MAPK provides one explanation for the opposite physiological effects of glucocorticoids and insulin (Fig. 7) . Upstream regulation of MAPK involves an array of signals that ultimately converge on Raf, which phosphorylates and activates MAPK kinase (MEK), leading to MAPK stimulation (9) . It is tempting to speculate that the activation of MAPK initiated by the insulin signal at the cell surface might antagonize receptor activity by altering receptor phosphorylation. Similarly, GR-mediated enhancement is diminished in cells transformed with H-Ras and v-Mos, which stimulate MAPK activity via Raf and MEK, respectively (22) . In contrast, inhibitors of the MAPK pathway, such as cAMPdependent protein kinase A, can potentiate receptor-dependent transcriptional enhancement (35, 43) . As multiple signaling pathways converge upon MAPK, it is conceivable that regulatory molecules that increase or decrease MAPK activity, such as cytokines, growth factors, and cAMP, will ultimately have an impact on receptor function (Fig. 7) .
Multiple MAPKs have been identified. Overlapping sets of MAPKs have been recently cloned in mammalian cells, and genetic studies in yeast have shown that MAPKs participate in at least three distinct signaling pathways (9) . The FUS3 and KSS1 pathway is regulated by G protein-linked pheromone receptors; another MAPK, HOG1, is regulated by a two-component system that may be involved in measuring osmolarity (17); MPK1 is regulated by a pKC homolog and is implicated in cell wall remodeling.
In mammalian cells, ERK1 and ERK2 are coordinately regulated by mitogenic stimuli; recently cloned MAPKs (SAPK and JNK) are activated by stress signals such as heat shock, inflammatory cytokines including tumor necrosis factor, and UV radiation (11, 26) ; the osmoregulated MAPK p38 is regulated in response to high osmolarity and by lipopolysaccharide treatment (16) . These different family members may have distinct or overlapping target specificities. It will be interesting to test whether other MAPK family members, such as JNK and p38, can also phosphorylate the receptor and affect its transcriptional activity.
Several groups have reported phosphorylation of the estrogen receptor (ER) by MAPK (2, 7, 24) . In contrast to GR, phosphorylation by MAPK appears to increase, rather than decrease the ER ligand-dependent transcriptional enhancement (24) . Furthermore, MAPK can stimulate the ligand-independent transcriptional activity of ER observed in certain cell types (7 may be an important regulatory input for modulating receptor transcriptional activity.
The CDKs also respond to various extracellular stimuli as well as to temporal changes in cell cycle positioning (34) . All CDKs are activated by association with cyclin regulatory subunits and by phosphorylation via CDK-activating enzymes which are known as CAKs (Fig. 7) . In addition, several inhibitors of CDK activity whose levels and activities are also modulated by extracellular stimuli have been recently identified (38) . As with the MAPK, the CDK family is large, and the actions of individual family members are varied. For example, cyclin B-CDC2 induces mitosis, cyclin E-CDK2 controls DNA replication (34) , cyclin D is synthesized in response to growth factors (1, 40) , and CDK5 is expressed in postmitotic neurons (39) , in which its actions remain to be determined. Conceivably, each cyclin-CDK complex phosphorylates a distinct set of specific target proteins or target residues. The evidence presented here suggests that cyclin A-CDK2 efficiently phosphorylates the receptor at S224 and perhaps modifies S232 more efficiently when S224 is phosphorylated. Our genetic evidence suggests that both G 1 and G 2 cyclin-CDK complexes affect receptor transcriptional enhancement to different extents in vivo. Thus, phosphorylation of the receptor appears to be influenced by multiple cyclin-CDK complexes.
Importantly, CDK enzymes also regulate processes other than the cell cycle. In S. cerevisiae, the Pho85-Pho80 cyclin-CDK complex is activated by high phosphate levels to phosphorylate and inactivate the Pho4 transcriptional regulator, which controls the expression of genes involved in phosphate metabolism (23) . In mammalian brain cells, CDK5 is complexed with a noncyclin protein and is probably involved in processes other than the cell cycle, since these neuronal cells do not divide (39) . Therefore, phosphorylation of the GR by a CDK may be part of a regulatory circuit unrelated to the cell cycle (34) . In fact, in all experiments presented here, we tested the effects of CDK mutations on receptor-mediated enhancement under conditions that preserved normal cell cycling. Therefore, we measured not the effects of cell cycle perturbations on receptor function but the effects of alterations in CDK activity.
An important challenge in the study of gene regulation is understanding how a single regulatory factor can specify multiple patterns of transcription. Regulation of expression of glucocorticoid responsive genes reflects a collaboration of multiple transcription factors at response elements. For example, the receptor can collaborate with heterodimeric AP1 factor c-jun/c-fos to either activate or repress transcription (12) . Our findings establish that in addition to using multiple factors to regulate one process, a single factor can receive, process, and integrate multiple signaling inputs. We propose that receptor phosphorylation directs and refines the receptor transcriptional response in order to fit particular cellular needs. The ability of the receptor to respond to extracellular signals via phosphorylation permits a plasticity in receptor action that, in conjunction with the steroid ligands, may be crucial in coordinating the various growth and metabolic processes managed by glucocorticoids.
